P. Mondejar Lopez (Molina de Segura (Murcia), Spain), C. Nissenbaum (manchester, United Kingdom), F. Frost (Liverpool, United Kingdom), F. Vermeulen (Leuven, Belgium)
Pregnancy in two patients with cystic fibrosis treated with lumacaftor/ivacaftor
C. Keßler (Muenster, Germany), A. Dübbers (Muenster, Germany), J. Große-Onnebrink (Muenster, Germany), H. Omran (Muenster, Germany)
|  |
Cystic Fibrosis Patients Eligible for Modulator Drugs: Data from Cystic Fibrosis Registry of Turkey
F. Çobanoglu (Ankara, Turkey), D. Dogru Ersöz (Ankara, Turkey), E. Çakir (AAAnkara, Turkey), T. Sismanlar Eyüboglu (AAAnkara, Turkey), S. Pekcan (AAAnkara, Turkey), G. Cinel (AAAnkara, Turkey), E. Yalçin (AAAnkara, Turkey), N. Kiper (AAAnkara, Turkey), V. Sen (AAAnkara, Turkey), H. Selimoglu Sen (AAAnkara, Turkey), Ö. Ercan (AAAnkara, Turkey), Ö. Keskin (AAAnkara, Turkey), S. Eltan (AAAnkara, Turkey), L. Muhammed Al Shadfan (AAAnkara, Turkey), H. Yazan (AAAnkara, Turkey), D. Ufuk Altintas (AAAnkara, Turkey), S. Sasihüseyinoglu (AAAnkara, Turkey), N. Sapan (AAAnkara, Turkey), S. Çekiç (AAAnkara, Turkey), H. Çokugras (AAAnkara, Turkey), A. Ayzit Atabek (AAAnkara, Turkey), T. Ramasli Gürsoy (AAAnkara, Turkey), A. Tana Aslan (AAAnkara, Turkey), A. Bingöl (AAAnkara, Turkey), A. Basaran (AAAnkara, Turkey), A. Özdemir (AAAnkara, Turkey), M. Köse (AAAnkara, Turkey), M. Hangül (AAAnkara, Turkey), N. Emiralioglu (AAAnkara, Turkey), G. Tugcu (AAAnkara, Turkey), H. Yüksel (AAAnkara, Turkey), Ö. Yilmaz (AAAnkara, Turkey), F. Orhan (AAAnkara, Turkey), Z. Gayretli Aydin (AAAnkara, Turkey), E. Topal (AAAnkara, Turkey), Z. Tamay (AAAnkara, Turkey), A. Süleyman (AAAnkara, Turkey), D. Can (AAAnkara, Turkey), C. Bal (AAAnkara, Turkey), G. Çaltepe (AAAnkara, Turkey), U. Özçelik (AAAnkara, Turkey)
| |
The pharmacokinetic of the main oral antibiotics in children with cystic fibrosis.
Y. Kondakova (Novosibirsk, Russian Federation), E. Kondratyeva (Moscow, Russian Federation), S. Zyryanov (Moscow, Russian Federation), I. Bondareva (Moscow, Russian Federation), V. Sherman (Moscow, Russian Federation), Y. Melyanovskaya (Moscow, Russian Federation)
|  |
Evaluation of adherence to medication treatment in pediatric patients with cystic fibrosis; a cross-sectional study
s. amini (Tehran, Islamic Republic of Iran), S. Jafarrangraz (Tehran, Islamic Republic of Iran), M. Modaresi (Tehran, Islamic Republic of Iran), K. Gholami (Tehran, Islamic Republic of Iran)
| |
Feasibility study of an intervention to increase treatment adherence in children with cystic fibrosis (CF)
E. France (Stirling, United Kingdom), G. Hoskins (Stirling, United Kingdom), E. Main (London, United Kingdom), S. Cunningham (Edinburgh, United Kingdom), C. Glasscoe (Liverpool, United Kingdom), B. Williams (Edinburgh, United Kingdom), E. Dhouieb (Edinburgh, United Kingdom), P. Hoddinott (Stirling, United Kingdom), S. Treweek (Aberdeen, United Kingdom), S. Hagen (Glasgow, United Kingdom), K. Semple (Stirling, United Kingdom)
| |
Development of Barrows Cards in enhancing self-management in Pediatric patient with Cystic Fibrosis
A. Bagnasco (Genoa, Italy), G. Aleo (Genoa, Italy), G. Catania (Genoa, Italy), M. Zanini (Genoa, Italy), L. Sasso (Genoa, Italy)
| |
Characteristics of cystic fibrosis patients diagnosed after false negative cystic fibrosis newborn screening results
P. Ergenekon (Istanbul, Turkey), E. Atag (Istanbul, Turkey), N. Bas I?kizoglu (Istanbul, Turkey), C. Yilmaz Yegit (Istanbul, Turkey), Y. Gokdemir (Istanbul, Turkey), E. Erdem Eralp (Istanbul, Turkey), B. Karadag (Istanbul, Turkey)
| |
Psychossocial and spiritual needs in Cystic Fibrosis patients
J. Grosse-Onnebrink (Muenster, Germany), C. Roch (Muenster, Germany), F. Stehling (Essen, Germany), M. Schiller (Homburg, Germany), S. Sutharsan (Essen, Germany), A. Buessing (Herdecke, Germany)
| |
Cystic Fibrosis in Iran
M. Modarezi (Tehraten, Islamic Republic of Iran), S. Navaie (tehranTehran, Islamic Republic of Iran), R. Shirzadi (tehrantehranTehran, Islamic Republic of Iran), M. Keyvanfar (tehrantehranTehran, Islamic Republic of Iran)
| |
Patient centred research: a model for involving cystic fibrosis (CF) patients in research planning
B. Bianco (Manchester, United Kingdom), H. Patel (Manchester, United Kingdom), E. Shaw Nunez (Manchester, United Kingdom), A. Brennan (Manchester, United Kingdom), S. Kirk (Manchester, United Kingdom), A. Horsley (Manchester, United Kingdom)
| |
Controlled inhalation improves total and peripheral lung deposition in CF
C. Bourke (Perth, Australia), M. Everard (Perth, Australia), S. Devadason (Perth, Australia), W. Ditcham (Perth, Australia), J. Depiazzi (Perth, Australia)
| |
Effectiveness of a mobile HFCWO device for airway clearance: impact on hyperinflation
G. Leemans (Kontich, Belgium), A. De Hondt (Kontich, Belgium), K. Ides (Wilrijk, Belgium), C. Van Holsbeke (Kontich, Belgium), D. Belmans (Kontich, Belgium), B. Becker (St. Paul Minneapolis, United States of America), K. Van Hoorenbeeck (Edegem, Belgium)
| |
Combining Inhalation by A Breath Actuated Nebuliser (BAN) With Exhalation Through An Oscillating Positive Expiratory Pressure Device (OPEP) Offers The Potential For Optimal Combined Therapy
M. Nagel (London, Canada), J. Suggett (London, Canada), V. Kushnarev (London, Canada), D. Coppolo (Albany, United States of America), A. Wesolowski (Pittsburgh, United States of America), T. Corcoran (Pittsburgh, United States of America)
| |
An evaluation of a novel disposable Oscillating Positive Expiratory Pressure (OPEP) device in children with Cystic Fibrosis.
K. O'Sullivan (Limerick, Ireland), V. Power (Limerick, Ireland), C. Dunne (Limerick, Ireland), L. O'Sullivan (Limerick, Ireland), B. Linnane (Limerick, Ireland), D. Mcgrath (Limerick, Ireland)
| |